Medicus Pharma (NASDAQ:MDCX) reported first quarter 2026 financial results on Thursday, highlighting progress across its SkinJect and Teverelix clinical programs while continuing efforts to strengthen ...
Medicus says Phase 2 data supports further development of SkinJect therapy for skin cancer Proactive uses images sourced from Shutterstock Medicus Pharma (NASDAQ:MDCX) said on Monday that new analysis ...
Pro Medicus Ltd (ASX: PME) shares have come roaring back since February. Is it too late to buy the ASX 200 healthcare share ...
Medicus Pharma Ltd. (NASDAQ: MDCX) (“Medicus” or the “Company”), a biotech/life sciences company focused on advancing the clinical development programs of novel and potentially disruptive therapeutic ...
Philadelphia, Pennsylvania--(Newsfile Corp. - August 4, 2025) - Medicus Pharma Ltd. (NASDAQ: MDCX) ("Medicus") and Helix Nanotechnologies Inc. ("HelixNano"), a Boston-based biotech company focused on ...
In April, Medicus Pharma Ltd. (NASDAQ:MDCX) agreed to acquire all of Antev’s issued and outstanding shares on a share exchange. Antev is a clinical-stage biotech company developing Teverelix, a ...
WINDHAM, N.H., July 16, 2026 /PRNewswire/ -- Medicus Healthcare Solutions, a leading locum tenens and workforce solutions ...
TORONTO, June 4, 2025 /CNW/ - Medicus Pension Plan ™ published its annual report today, announcing its strong funded status of 152% as of January 1, 2025, along with a robust return of 9.1% in 2024.
The Pro Medicus share price is rallying again as investors respond to the company’s latest move in healthcare AI.
Let's put Pro Medicus's jaw-dropping share price aside for a moment and instead zoom in on what's driving its valuation. Because for all the noise about how expensive the stock looks, the real story ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results